Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

1.612 +0.042 (+2.65%)
Streaming Delayed Price Updated: 3:30 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,934
Open 1.570
Bid (Size) 1.590 (9)
Ask (Size) 1.620 (6)
Prev. Close 1.570
Today's Range 1.560 - 1.640
52wk Range 1.110 - 4.160
Shares Outstanding 64,393,294
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga

Performance

YTD
-44.62%
-44.62%
1 Month
+21.17%
+21.17%
3 Month
+6.73%
+6.73%
6 Month
-15.62%
-15.62%
1 Year
-27.41%
-27.41%

More News

Read More
Earnings Outlook For GlycoMimetics
Via Benzinga
GlycoMimetics: Q1 Earnings Insights
Via Benzinga
Earnings Preview For GlycoMimetics
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Via Talk Markets
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
From GlycoMimetics, Inc.
Via Business Wire
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Via Benzinga
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.